This Article Full Text Full Text (PDF) All Versions of this Article: 46/6/1381    most recent 01.HYP.0000190041.61737.fdv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yuan, K. Articles by Kim, S. H. Search for Related Content PubMed PubMed Citation Articles by Yuan, K. Articles by Kim, S. H.

(Hypertension. 2005;46:1381.)
© 2005 American Heart Association, Inc.

Original Articles

Adenosine-Stimulated Atrial Natriuretic Peptide Release Through A₁ Receptor Subtype

From the Department of Physiology, Medical School, Center for Healthcare Technology Development, Chonbuk National University, Jeonju, Korea.

Correspondence to Suhn Hee Kim, MD, PhD, 2-20 Keum-Am-Dong-San, Department of Physiology, Chonbuk National University Medical School, Jeonju 561-180, Korea. E-mail shkim{at}chonbuk.ac.kr

Adenosine acts as an important protector of ischemic myocardium through coronary vasodilation and the depression of cardiac contractility. The protective effect of adenosine may partly relate to the cardiac hormone atrial natriuretic peptide (ANP). The aim of the present study was to investigate the effects of adenosine and the adenosine receptor subtype on atrial hemodynamics and ANP release using isolated perfused beating rat atria. Adenosine, a nonselective adenosine receptor agonist, increased the ANP release with negative inotropism in a dose-dependent manner. Adenosine-stimulated ANP release was attenuated by a selective A₁ antagonist but not A_2A antagonist or A₃ antagonist. The order of potency of the various agonists for the ANP release was A₁ agonists>>A₃ agonist= adenosine>A_2A agonist. The order of potency for the negative inotropy was A₁ agonists>adenosine=A_2A agonist>A₃ agonist. The negative inotropism and ANP release by a specific A₁ agonist (N⁶-cyclopentyl-adenosine) were also attenuated by A₁ antagonist but not A_2A antagonist or A₃ antagonist. Treatment with A₁ agonist resulted in a decrease of cAMP contents in atria and perfusates. The agonist-stimulated ANP release was significantly attenuated in the presence of forskolin, isoproterenol 8-Br-cAMP, or an adenylyl cyclase inhibitor. These results suggest that the A₁ receptor subtype is responsible for the adenosine-induced ANP release and negative inotropism through adenylyl cyclase–cAMP pathway.

Key Words: adenosine • natriuretic peptides • cyclin AMP • heart • hypertension, experimental • receptor • kidney

This article has been cited by other articles:

				A. M. Richards Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use Hypertension, July 1, 2007; 50(1): 25 - 30. [Full Text] [PDF]